Gilead Compares Stribild To Prezista In Seeking Exclusivity For Fixed Dose Combinations
This article was originally published in The Pink Sheet Daily
Executive Summary
Gilead requests five-year marketing exclusivity for two of the components in its HIV Quad treatment Stribild; citizen petition says award should not depend on whether a new active moiety is approved first as a single entity product or as part of a fixed-dose combination.